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Background: It has been suggested that polymorphisms in Toll-like Receptors (TLRs) are associated with Rheumatoid
Arthritis (RA), but the implicated alleles have differed between studies. The aim of this investigation was to explore
whether polymorphisms of TLR genes are associated with RA in a predominantly Caucasian population from Denmark
using a case–control approach.
Findings: DNA samples (3 university hospital outpatient clinics) were obtained from patients with RA (n = 704) and
healthy controls (n = 639) in a Danish population. TLR single nucleotide polymorphisms (SNPs) were selected based on
the previously reported associations with chronic autoimmune diseases. Genotyping for the TLR SNPs was performed
using Sequenom Multiplex technology.
We identified one SNP in TLR3, [(rs3775291, P = 0.02, OR (95% CI) 1.31 (1.1087-1.5493)] significantly associated with the
whole RA cohort. Subgroup analysis according to IgM rheumatoid factor (RF) and anti-cyclic citrinullated peptide (CCP)
status suggested a significant association of sero-negative RA with the rs3775291 A allele and disease activity in this
subset.
Conclusion: These observations on a RA population of Danish ancestry suggest that variations in the TLR3 locus may
be implicated in the pathogenesis of sero-negative RA. Since this TLR3 SNP has previously been associated with
systemic lupus erythematous (SLE), the present findings support the notion that TLR3 genetic variants may represent
a common risk factor in different chronic inflammatory conditions, including RA and SLE.
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Rheumatoid arthritis (RA) is a chronic, systemic and in-
flammatory joint disease that leads to bone and cartilage
destruction, as well as a wide variety of extra-articular
manifestations [1]. The causes of RA are largely unknown,
however, the role of genetic factors is evident, with the
major histocompatibility complex (MHC) region as major
contributor [2]. In spite of that, this association accounts
for only one-third of the genetic susceptibility, as non-* Correspondence: laska@hum-gen.au.dk
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unless otherwise stated.Human Leukocyte Antigen (HLA) genes are also known
to be involved [3].
Toll-like receptors (TLRs) are involved in the detection
of environmental signals and the regulation of dendritic
cell (DC) function and are therefore the subject of investi-
gations in autoimmunity. TLRs are expressed both by
immune cells and by resident cells of the joint, including
fibroblast-like synoviocytes (FLS), which in RA play a key
role by producing cytokines that perpetuate inflammation
and proteases that contribute to cartilage destruction [4].
Several studies have examined the potential pathogenetic
contribution by TLR polymorphisms to the manifestations
of RA, but the results have been conflicting [5-7]. We havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






State Case 66 319 319 704
Cntl 49 240 350 639
Total 115 559 669 1343
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associated with Systemic Lupus Erythematous (SLE) in a
Danish lupus cohort [8]. Here, we hypothesized that some
of the SLE associated markers might likewise be associated
with RA. To test this, we investigated potential associations




704 RA patients were randomly recruited from 3 univer-
sity hospital outpatient clinics. All patients fulfilled the
American College of Rheumatology 1987 revised criteria
for RA [9]. 639 controls were healthy individuals without
RA, autoimmune or systemic disorders nor a family history
of RA. The study was approved by the regional ethics
committees of Southern and Mid Denmark (no S20090051
and 1-10-72-388-12). Informed and written consent was
provided by all the participants.
Characterization of disease activity and outcomes
in patients
Health Assessment Questionnaire (HAQ score, 0 to 3),
Visual Analogue Scale (0 to 10) (VAS pain, global and
doctor) and Disease Activity Score in 28 joints (DAS28
scale, 0 to 10) were calculated. Anti-CCP (IgG antibodies)
was determined by a second-generation ELISA with 25
μg/ml as the cut-off point. Serum C-reactive protein
(CRP; mg/ml) and erythrocyte sedimentation rate (mm/h)
were measured using standard laboratory methods. IgM-
RF was detected by ELISA; the cut-off level was >16 IU/
ml (~95th percentile of healthy subjects).
Nucleic acid extraction
Genomic DNA was isolated from peripheral blood sam-
ples using a standard method, which included separation
and lysis of the nuclear cells, treatment with proteinase K,
extraction with phenol-chloroform and ethanol precipita-
tion. DNA concentrations were determined using a
Quanti-iT™ PicoGreen® ds DNA kit (Life Technologies
Europe BV, DK).
Genotyping
SNPs selected for the assays were primarily functional,
and previously reported to be associated with SLE or
other autoimmune disease [8]. Genotypes of 22 TLR SNPs
were determined by Sequenom MassArray technology
(Sequenom iPLEX assay, San Diego, USA), in accordance
with the manufacturer’s instructions. The reactions were
analyzed by MALDITOF mass spectrometry on the
Sequenom equipment, and the results were analyzed using
the MassARRAY Typer 4.0. The SNPs and primers
sequenced were published previously [8].Statistical analysis
Frequencies of the TLR genotypes were tested for
Hardy-Weinberg equilibrium among the controls using
the standard goodness-of-fit test. Similarity of genotype
and allele distribution between patients and controls was
tested with chi-square tests for 3 × 2 contingency tables.
Differences in the disease characteristics between patients
were analyzed using Student’s t test or Mann–Whitney U
test. Corrections for false rate discovery were applied
using Benjamin and Hochberg formula. Power analysis
revealed that with 704 patients and 639 controls we were
able to demonstrate a 1.6 fold increase in frequency of the
particular genotypes in RA patients compared with con-
trols ( power 95%, ɑ = 0.05).
Results
Association of TLR SNPs with RA in a Danish population
Of 22 polymorphisms investigated, only rs3775291 located
in TLR3, showed significant allelic association with RA
in this Danish cohort. The carrier frequency of the
rs3775291A allele was significantly increased in RA pa-
tients compared with healthy controls (p(A)cases =0.32 vs
p(A) controls =0.26) [P =0.02, OR (95% CI) 1.31 (1.1087-
1.5493)]. The genotype frequencies are given in the
supplemental data, Table 1. The TLR3 marker was not as-
sociated with age at inclusion, neither in the RF-negative
nor the total groups. Nor was there any effect on age at
onset. For the remaining TLR SNPs no significant associa-
tions were observed between the genotypes or allele
frequencies and the presence of RA. However, several
other TLRs showed weaker signs of SNP association.
Association of TLR3 rs3775291 and clinical parameters
To analyze the relation of rs3775291 to disease manifesta-
tions we recoded the SNP into the numbers of A-alleles
present in the genotype, i.e. AA = 2; AG = 1 and GG= 0,
corresponding to co-dominance of the investigated marker.
Subsequently, we used regression analysis to calculate the
regression coefficient to the numbers of A’s, thereby enab-
ling us to evaluate the relevance of the marker. Stratifica-
tion according to IgM-RF among the cases revealed no
evidence of different associations between the compared
subgroups [(coefTLR =0.034 (P = 0.63)].
Table 2 Association of various clinical RA markers with
TLR3 rs3775291
RF negative RF positive
Parameter coefTLR p-coef coefTLR p-coef
spd 0.032 0.689 0.088 0.057
Anti-CCP 0.075 0.355 −0.004 0.939
Swollenjointcount(28) 0.159 0.048 −0.016 0.724
Painfuljointcount(28) 0.274 0.0006 −0.017 0.717
CRP(mg/l) −0.030 0.713 0.006 0.604
VASpatientglobal 0.099 0.222 0.006 0.984
DAS28CRP 0.245 0.002 0.014 0.760
HAQscore 0.014 0.989 −0.030 0.514
Spd, surfactant protein D (serum); Anti-CCP, anti-cyclic citrullinated peptide
antibodies; Swollenjointcount(28), swollen joint count (maximum 28 joints);
Painfuljointcount(28) tender joint count (max 28 joints); CRP, c-reactive protein
(mg/l); VASpatientglobal, Visual Analogue Scale; DAS28CRP, composite
measurement Disease acitivity 28 joint crp; HAQscore, Health Assessment
Questionnaire (HAQ score, range 0-3).
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calculated the remaining clinical parameters accordingly
(Table 2). Even though this stratification reduced the
number of subjects eligible for the analysis, subgroups
maintained numerosity comparable with the entire study
cohort. Notably, three parameters (swollen join count
28, painful joint count 28, DAS28CRP), relating to activeFigure 1 Relation of disease activity scores, as measured by DAS28, t
median marked with black line, and hinges indicating 25th and 75th perce
interquartile range. The circles represent outliers and the asterisks are extrejoint disease in RA were associated with the TLR3
marker among RF-negative, but not among RF-positive
patients. The results remained significant after Bonferroni
correction for the multiplicity of testing. RF-positive RA
occurred significantly earlier among women than men
(onset =47 vs 50 years, p =0.006). RF-negative RA had
similar onset in both genders (55 years). There was a non-
significant tendency that onset occurred later in homozy-
gote rs3775291AAs than in heterozygote AGs among the
RF-negative (onset =60 vs. 54 years, p =0.17). A similar
tendency was present in the RF-positive (onset =51 vs. 48
years, p =0.19).
Figure 1 presents the relation of disease activity score,
as measured by DAS28, to the TLR3 rs3775291 in the
two subpopulations. The figure also shows the relation
of the number of painful joints to the marker. Similar
results were obtained when patients were segregated
into anti-CCP positive and anti-CCP negative RA.
Discussion
A variety of experimental models have suggested a role for
TLRs in the pathogenesis of RA [10]. The present data
provide evidence for an association between the TLR3
gene variant (rs3775291) and RA. In addition, disease
activity measures including DAS28 and swollen joint
counts were associated with rs3775291 in sero-negativeo the TLR rs3775291 in the two subpopulations. The box plot with
ntile. Whiskers represent extreme values within 1.5 times the
me outliers.
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has no influence in sero-positive RA patients, but any
effect may be masked by the greater influence of sero-
positivity.
The results of the present study support the notion
that the genetic background may differ between IgM
sero-positive vs- sero-negative RA thereby contributing
to the concept of rheumatoid arthritis as 2 separate and
distinctive disease entities [11]. For example, previous
studies have suggested that sero-positive and sero-
negative RA have distinct MHC class II cell surface
receptor (HLA-DR) associations, especially in disease of
early onset, in addition to well established clinical differ-
ences [3]. Although the functional consequences of gen-
etic variability in the TLR3 locus have not been defined
in detail it is tempting to speculate that polymorphisms
in the TLR3 gene may not only have an impact on the
risk of developing sero-negative RA but may also play a
role as disease activity modifier in sero-negative RA as
reflected by the association with DAS28 and swollen
joint count.
The SNPs analyzed in this study were selected based
on previous associations with autoimmune diseases and
tagging properties, and are contained within TLR
sequences. Some TLRs polymorphism have been shown
to be associated with susceptibility and the clinical pro-
file of RA, but few studies have been conducted in the
past on each of these associations [5,12]. To the best of
our knowledge, this is the first study demonstrating an
association between the TLR3 polymorphism rs3775291
and disease activity in RA. Of note, rs3775291 was in-
cluded as a candidate marker in genome-wide associ-
ation studies (GWAS) on RA in a Spanish population,
but the analysis did not reveal a genome-wide signifi-
cance level [13]. This outcome could be explained if
much of the missing genetic control in RA is due to
gene variants that are too rare to be picked up by
GWAS studies and have relatively large effects on risk.
The rs3775291 A allele has previously been associated
with female SLE in a Danish population and with sub-
acute sclerosing panencephalitis in a Japanese study [8,14].
Moreover, genetic studies have provided evidence con-
cerning the role of rs3775291, Leu412Phe with respect to
the susceptibility to viral infections [15]. Thus, although
the functional consequences of the rs3775291 A poly-
morphism in RF sero-negative RA have not been settled,
our findings may lend support to an infectious trigger in
sero-negative rheumatoid arthritis.
In summary, this study provides evidence that the TLR3
rs3775291 locus associates with the occurrence and
disease activity in sero-negative RA. This and previous
findings in SLE patients [8] suggests that TLR3 genetic
variants may represent shared pathogenetic pathways in
chronic inflammatory conditions including RA and SLE.Competing interests
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